Design and Synthesis of N-[(4-Methoxyphenoxy)carbonyl]-N-[[4-[2-(5- methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine [Muraglitazar/BMS-298585], a Novel Peroxisome Proliferator-Activated Receptor α/γ Dual Agonist with Efficacious Glucose and Lipid-Lowering Activities
- 13 November 2004
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 48 (6), 2248-2250
- https://doi.org/10.1021/jm0496436
Abstract
Muraglitazar/BMS-298585 (2) has been identified as a non-thiazolidinedione PPAR α/γ dual agonist that shows potent activity in vitro at human PPARα (EC50 = 320 nM) and PPARγ (EC50 = 110 nM). Compound 2 shows excellent efficacy for lowering glucose, insulin, triglycerides, and free fatty acids in genetically obese, severely diabetic db/db mice and has a favorable ADME profile. Compound 2 is currently in clinical development for the treatment of type 2 diabetes and dyslipidemia.Keywords
This publication has 10 references indexed in Scilit:
- TesaglitazarDrugs of the Future, 2003
- NetoglitazoneDrugs of the Future, 2002
- (−)3-[4-[2-(Phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic Acid [(−)DRF 2725]: A Dual PPAR Agonist with Potent Antihyperglycemic and Lipid Modulating ActivityJournal of Medicinal Chemistry, 2001
- Current Therapies and Emerging Targets for the Treatment of DiabetesCurrent Pharmaceutical Design, 2001
- Rosiglitazone in the treatment of type 2 diabetes mellitus: a critical reviewClinical Therapeutics, 2000
- PioglitazoneDrugs, 2000
- A Ureido-Thioisobutyric Acid (GW9578) Is a Subtype-Selective PPARα Agonist with Potent Lipid-Lowering ActivityJournal of Medicinal Chemistry, 1999
- Hyperglycemia and cardiovascular disease in type 2 diabetes.Diabetes, 1999
- (3-Substituted benzyl)thiazolidine-2,4-diones as structurally new antihyperglycemic agentsBioorganic & Medicinal Chemistry Letters, 1999
- Identification of peroxisome proliferator-activated receptor ligands from a biased chemical libraryCell Chemical Biology, 1997